To determine whether abnormal kinetics of insulin's biologic actions contribute to the overall insulin resistance in obesity, we compared the rate of activation and deactivation of insulin's effects to stimulate glucose disposal rate (Rd) and inhibit hepatic glucose output (HGO) in 12 nonobese and 10 obese subjects using the euglycemic clamp technique at insulin infusion rates of 15,40,120, and 1,200 mU/M2 per min. In both groups, stimulation of Rd was faster the higher the insulin infusion rate and the time to reach half maximal stimulation (Aso value) in normals was 52±4, 44±2, 29±3, and 21±2 min at infusion rates of 15, 40, 120, and 1,200 mU/M2 per min, respectively. In the obese subjects, the rate of activation was slower (higher As5 values) with A5. values of 74±6, P < 0.001 (compared to normal), 64±8 min., P < 0.001, and 28±3 mm, P < 0.01, at the 40, 120, and 1,200 mU/M2 per min insulin infusions. Deactivation of the insulin effect to stimulate glucose disposal rate (Rd) was faster in the obese group compared with normal individuals after all comparable insulin infusions. In summary: (a) for both groups, the higher the insulin infusion rate, the higher the steady state Rd value, the faster the rate of activation and the slower the subsequent rate of deactivation. (b) In insulin-resistant obese subjects, the rate of activation of insulin action was slower and the rate of deactivation faster at comparable insulin infusion rates. (c) The rate of suppression of HGO was comparable in normal and obese subjects, but the rate of recovery of HGO back to basal values was faster in the obese group.
Introduction
The effects of insulin to stimulate glucose disposal are impaired in obesity (1, 2) , and this is a well-described phenomenon termed insulin resistance. Qualitative estimates of insulin resistance in obesity have been available for a number of years (3, 4) , but only relatively recently have quantitative assessments become available (1, 2, 5) . These later studies have largely involved measurements of the biologic effectiveness of a given concentration of insulin under steady state conditions. For obesity as well as other conditions in which insulin action is impaired (6) , in vivo insulin resistance thus is usually defined as a decreased ability of a constant plasma insulin concentration to stimulate overall glucose disposal under steady state conditions where the hormonal effect has plateaued. The glucose clamp technique is an ideal method to achieve these goals and much valuable information has been learned with this approach (7) . It takes several hours before steady state biologic effects of constant insulin infusions are reached, however, and this clearly does not reproduce the phasic way in which insulin is delivered into the circulation under physiologic conditions of meal ingestion. Furthermore, assessments confined to steady state measurements of insulin action will not detect kinetic alterations in the onset (activation) or offset (deactivation) of insulin's biologic effects. Indeed, in view of the fact that in response to food, insulin is secreted in a phasic rather than a constant manner, a defect in the dynamics of insulin action might be a physiologically more important manifestation of insulin resistance than reduced steady state hormonal effects.
To evaluate the above ideas, we have used a modification of the euglycemic glucose clamp technique (8) to test the hypothesis that a common human insulin resistant state, i.e., obesity, is characterized by abnormally slow activation and rapid deactivation of insulin's effects to stimulate peripheral glucose uptake. In this report, we show that the kinetics ofinsulin action are abnormal in obesity and suggest that these kinetic defects represent a physiologically important manifestation of insulin resistance.
Methods Materials
Regular human insulin was supplied by the Eli Lilly Co., Indianapolis, IN. [3-3H] Glucose was purchased from New England Nuclear (Boston, MA).
Subjects
The study group consisted of 12 lean control subjects and 10 obese subjects. Clinical and metabolic characteristics ofthe subjects are summarized in Table I . The fasting serum glucose and insulin levels represent the mean of at least three determinations done on consecutive days. All subjects were admitted to the Special Diagnostic and Treatment Unit of the Veterans Administration Medical Center, San Diego. Studies were approved by the Human Subjects Research Review Committee and all subjects gave written informed consent.
Diet
All subjects were placed on a weight maintaining (32 kcal/kg per d) liquid formula diet containing 45% carbohydrate, 15% protein, and 40% fat. The diet was divided into three portions, given at 8:00 a.m., 12:00 a.m., and 5:00 a.m., containing 20, 40 , and 40% of the total caloric intake, respectively. All subjects equilibrated on this diet for at least 48 h before any studies were performed. Each study was carried out on a separate day. prevented by infusion ofK2PO4. The overall rate ofglucose disposal was assessed isotopically in 20-min intervals as described below. After 3 h, the insulin infusion was stopped and deactivation ofthe hormone's effects was assessed. The glucose concentration was kept constant by continuously adjusting the glucose infusion rate and measurements of glucose turnover and serum insulin concentration were continued for 120-180 min following cessation ofthe insulin infusion. After discontinuation of the 1,200 mU/M2 per min insulin infusion at 3 h, the experiment was stopped without studying deactivation of the hormone effect.
Measurement ofglucose turnover. The glucose turnover rate was assessed during the basal state as well as during the activation and deactivation phase of the studies by infusion of [3-1H-glucose in a primed continuous manner (an initial bolus of 60 MCi was followed by a continuous infusion rate of 0.6 uCi/min). Blood samples were taken at 20-min intervals for determination of glucose concentration and specific activity. Glucose turnover was calculated using the Steele equations in their modified derivative form (9), for non-steady state conditions. Measurement ofhepatic glucose output (HGO).' In the basal state, hepatic glucose production is the only source of glucose entering the system; therefore, the basal glucose appearance rate (R.) equals basal hepatic glucose output (HGO). During the insulin infusion (and subsequent deactivation phase), the rate of HGO was calculated as the difference between R. and the infusion rate of exogenous glucose.
Calculation of incremental glucose disposal rate (IGDR). The activation and deactivation of peripheral glucose disposal was assessed by calculating the incremental glucose disposal rate (IGDR). IGDR was defined as the difference between the basal glucose disposal rate and the measured Rd values during the insulin infusion and subsequent deactivation phase (8).
1. Abbreviations used in this paper: A5o, half time activation; D50, half time deactivation; HGO, hepatic glucose output; IGDR, incremental glucose disposal rate; R., glucose appearance rate; Rd, rate of glucose disposal.
Analytical methods
Blood for serum glucose determination was drawn and centrifuged immediately using an Eppendorf microfuge (Brinkmann Instruments, Westbury, NY). Glucose was measured by the glucose oxidase method using an automated glucose analyzer (YSI, model 23A, Yellow Springs Instruments, Yellow Springs, OH). Blood for determination of serum insulin was collected in untreated tubes and allowed to clot at room temperature. Blood for glucagon determination was collected into tubes containing Trasylol and allowed to clot at room temperature. After separation all samples were stored at -200C until analysis. Serum insulin levels were determined by a double antibody radioimmunoassay (10) and serum glucagon was measured by the charcoal separation method of Unger (I 1).
Data analysis
Glucose turnover data were calculated using the optimal segments method originally described by Finegood ( 12) . Statistical calculations were performed on the CLINFO system of the Clinical Research Center at the University ofCalifornia at San Diego Medical Center. Statistical analysis was performed using a two-way analysis of variance adjusted for repeated measures (BMDP 2V Software) and the Student's t test for paired and unpaired data as indicated. Correlation coefficients were calculated using a linear regression analysis.
Results
Oral glucose tolerance test. Fasting serum glucose levels were 88±3 mg/dl and 98±4 mg/dl in the nonobese and obese group, respectively. After an oral glucose load of 75 g, six obese and all nonobese subjects had normal glucose tolerance and four obese subjects exhibited impaired glucose tolerance according to the criteria of the National Diabetes Data Group (13). During the glucose tolerance test, serum glucose as well as serum insulin levels were significantly higher in the obese than in the nonobese subjects (Fig. 1) .
Serum insulin levels. The serum insulin levels during and after the different insulin infusion rates in nonobese and obese subjects are summarized in Fig. 2 A insulin infusion. This analysis is presented in Fig. 4 for both groups.
The fractional rate ofactivation ofinsulin's effect to stimulate glucose disposal increased progressively with increasing insulin infusion rate. In the normal subjects, the A50 IGDR values were 52±4, 44±2, 29±3, and 21±2 min at insulin infusion rates of 15, 40, 120, and 1,200 mU/M2 per min (Fig. 4 A and Table II ). An increase in the insulin infusion rate thus led to higher steady state insulin levels, higher IGDR values, and lower A50 IGDR values (faster activation). An identical trend was observed in the obese subjects (Fig. 4 C) . The A50 IGDR values were 74±6, 64±8, and 28±3 min at the 40, 120, and 1,200 mU/M2 per min insulin infusion studies, respectively, (at 15 mU/M2 per min, the increase in Rd was negligible in the obese subjects precluding estimation of either activation or deactivation values).
Although the phenomenon of increasing activation rates at higher insulin infusion rates was observed in both groups, marked differences in A50 IGDR values existed when the normal and obese subjects were compared (Table II) . When comparing the groups at the same insulin infusion rates, activation values were 44±2 vs. 74±6 min (P < 0.001) during the 40-mU/M2 per min study, 29±3 vs. 64±8 min (P < 0.001), during the 120-mU/M2 per min study, and 21±2 vs. 28±3 (P < 0.01) during the 1,200-mU/M2 per min study, in the normal vs. obese subjects, respectively. 2001- demonstrate that the rate at which insulin stimulates overall in vivo glucose uptake is slower in obesity and indicate that these differences are not due to differences in pharmacokinetics of insulin in plasma or its access td tissue sites of action. Deactivation ofinsulin stimulation ofglucose disposal. The deactivation curves were linearized by log transformation and the absolute rate of deactivation (i.e., slope) was calculated. In contrast to the rates ofactivation, absolute rates (slopes) ofdeactivation were found to be similar at all insulin concentrations in the normals and the obese subjects. The calculated slopes were -0.33+0.11, -0.46+0.13, and -0.32±0.06 X 10-2 in the control subjects at insulin infusion rates of 15, 40, and 120 mU/ M2 per min, vs. -0.30±0.12 and -0.43±0.09 X 10' in the obese subjects at insulin infusion rates of 40 and 120 mU/M2 per min. However, since steady state Rd and IGDR values were significantly higher the greater the insulin infusion rate, in view of similar absolute slopes of the deactivation curves, it follows that the fractional or relative rate, as estimated by the half time ofdeactivation (DI0 IGDR) ofinsulin's effect to stimulate glucose disposal, decreased progressively with increasing insulin infusion rates in both groups (Fig. 4 , Table II were not carried out after these studies). Increasing the insulin infusion rate thus led to higher steady state insulin and Rd levels, but progressively higher D50 IGDR values (slower deactivation). The same trend was observed in the obese subjects; the D50 IGDR values were 31±6 and 46±2 during the 40-and 120-mU/M2 per min studies, respectively (Fig. 4 D) . As mentioned earlier, deactivation values were not measured during the 15-mU/M2 per min study since stimulation of Rd in the obese group was negligible (Fig. 3 B) .
The relationship between decreasing rates of deactivation with higher IGDR values was noted in both groups, but striking differences in D50 IGDR values were observed between the groups when comparisons were made at comparable insulin infusion rates (Fig. 4, Table II) . When comparing deactivation rates at the same insulin infusion rates, the D50 IGDR values were 43±2 vs. 31±6 min (P < 0.01) after the 40-mU/M2 per min infusion and 78±5 vs. 46±2 (P < 0.01) after the 120-mU/ M2 per min infusion in the normal and obese subjects, respectively. The rate of deactivation of insulin action thus was faster in the insulin-resistant obese subjects after the same steady state insulin infusion study. However, as discussed above, the steady state glucose disposal rates were always lower in the obese groups compared to normals at the same insulin infusion rate. We also compared the rates of deactivation between the two groups, therefore, after achieving comparable glucose disposal rates, but at different insulin infusion rates. As seen in Fig. 5 Effect of insulin to suppress HGO. Steady state suppression ofHGO was complete (100%/ suppression) in the normal subjects at insulin infusion rates of 40 mU/M2 per min and higher (Fig.  6 B and C) , and HGO was 90% suppressed at the end of the 15 mU/M2 per min infusion (Fig. 6 A) . In contrast, HGO was only -80% suppressed in the obese group (P < 0.05 compared with control) during the 15 (Fig. 6 A) and 40 mU/M2 per min (Fig.  6 B) infusions, but was completely suppressed at the higher insulin infusion rates. Under steady state conditions, the liver thus is less sensitive to the suppressive effects of physiologic insulin concentrations on HGO in obesity, indicating resistance to this hepatic action of insulin. In theory, HGO cannot be more than 100% suppressed, but occasional slightly negative values were observed at high rates ofRd (Fig. 6 ). This has also been reported by other groups, and although the negative values are quantitatively small, the reason for this remains unclear.
Insulin acted more rapidly to suppress HGO than it did to stimulate glucose disposal at all insulin levels in both groups. There was a trend toward faster rates of suppression the higher the insulin infusion rate (Fig. 6 any insulin infusion between the normal and obese groups. HGO was completely suppressed in both groups within 15 min at the highest insulin infusion (1,200 mU/M2 per min) rate (data not shown).
Rate ofrecovery ofHGOfrom insulin suppression. Following cessation of the insulin infusions, the recovery of HGO was far more rapid in the obese compared with the control group (Fig.  6) . The half time for recovery of HGO (calculated as the time at which HGO increased by 50% of the absolute amount of suppression achieved at steady state) thus was 35±6 vs. 54±2 min (P < 0.01) for the obese and normal groups, respectively, after the 1 5-mU/M2 per min infusion (Fig. 6 A) . Following the 40- (Fig. 6 B) and 120-mU/M2 per min (Fig. 6 C) Effect of insulin on serum glucagon levels. Basal glucagon values were 165±22 pg/ml in the obese group and 118±6 pg/ ml in the control subjects (P < 0.01). During all insulin infusions, glucagon levels suppressed comparably (25-35%, P < 0.001) by 180 min in the control subjects (Fig. 7 A) and following discontinuation ofthe insulin infusion, glucagon values remained suppressed for up to 180 additional minutes relative to the basal values. In the obese group (Fig. 7 B) , glucagon levels did not change significantly at any time point during the 15-mU infusion. During the 40-mU study, glucagon levels were significantly suppressed by 15 and 17% (P < 0.05) at 120 and 180 min, respectively, and this degree of suppression was less (P < 0.05) compared to the normal subjects at the same insulin infusion rate; glucagon levels rapidly returned to baseline values following cessation of the 40-mU insulin infusion. During the higher dose insulin infusions, glucagon suppression was comparable in the obese and normal groups, but recovered toward baseline more rapidly (i.e., 120 mU/M2 per min insulin infusion) in the obese subjects.
Correlation between steady state glucose disposal and rates ofactivation and deactivation. In individual obese and control subjects, the negative correlation between steady state IGDR (18) , given the relatively rapid rise and fall in plasma insulin after meals, it is highly unlikely that steady state biologic effects of insulin are ever achieved in the physiologic state. If kinetic defects in the rate of onset and/or deactivation of insulin action exist, such defects thus might be of physiologic importance. The current studies demonstrate that in insulin-resistant obese subjects, the rate of activation of insulin's effects on glucose disposal is slower and the rate of deactivation of these effects faster than in normals.
It is suggested that these kinetic abnormalities of insulin action may be a functionally more important aspect of insulin resistance under physiologic meal eating conditions than the reduced steady state biologic effects of insulin that have been previously described (1, 2,5 ).
In the current group of obese subjects the steady state effects of insulin to stimulate overall glucose disposal are decreased at all insulin concentrations. The magnitude of the decrease is greater the lower the insulin concentration. Essentially no stimulation of glucose disposal thus was observed in the obese group at the lowest insulin infusion rate (15mU/M2 per min), which produced mean insulin levels of -45,uU/ml, and compared with controls, the decrease in insulin-stimulated glucose disposal was 44, 27, and 28% at insulin levels of 100, 300, and 10,000
,gU/ml, respectively. The greater impairment of insulin action at the lower insulin levels indicates decreased insulin sensitivity (19) , and the decreased glucose disposal at maximal insulin levels demonstrates decreased insulin responsiveness (19) .
In addition to these steady state manifestations of insulin resistance, marked kinetic abnormalities of insulin action were also observed. In normal subjects, the rate of activation of insulin's stimulatory effects on glucose disposal increased the higher the insulin infusion rate (and higher the Rd). At the lowest insulin infusion rate (15 mU/M2 per min, insulin level -45 gtU/ml) the steady state Rd was 168±10 mg/kg per min and the halftime (A50 IGDR) to achieve this value was 52±4 min; at the highest insulin infusion rate (1,200 mU/M2 per min, plasma insulin -10,000 AU/ml) the steady state Rd value was 422 mg/M2 per min and the half time to reach this value was only 21±2 min.
Therefore, as the insulin concentration increases, not only does the Rd rise, but so does the effect of insulin to accelerate the cellular processes that govern the fractional rate of rise in glucose disposal.2 A similar phenomenon was seen in the obese subjects.
The higher the insulin infusion, the faster the activation rate for stimulation of glucose disposal; the Amo IGDR values was 74±6 min at -100 MU/ml (40 mU infusion) and 28±3 min at -10,000 ,U/ml (1, 200 mU infusion). However, at each insulin infusion rate the A50 IGDR values were significantly lower in obesity, indicating a decrease in the rate of activation of insulin action. On the other hand, since activation was faster the higher the Rd in either group, it seemed possible that the slower rate insulin action in obesity was a reflection of the decreased steady state effects of insulin to stimulate Rd. To assess this possibility we compared the rates of activation at similar levels of glucose 2. It should be noted that this relationship refers to the steady state Rd values and the fractional (or relative) rates as assessed by A50 values. The relationship is even stronger if absolute rates of activation (as calculated from the slopes of the absolute Rd values in Fig. 3 ) are considered, but this is simply because absolute rates of activation are highly dependent on the height of the final Rd value. disposal between the two groups (Fig. 5) . The steady state Rd values for the normal individuals during the 15-and 40-mU insulin infusions thus were similar to the Rd values in the obese group at the 40-and 120-mU infusions, respectively. At these comparable levels of glucose disposal, despite higher insulin infusion rates in the obese, the activation rates were still significantly slower (higher A50 IGDR values) in the obese group. In addition to reduced steady state insulin effects, insulin-resistant obese subjects thus demonstrate a striking kinetic defect in the rate of onset of insulin's stimulatory effects on glucose disposal. It should also be noted that at the pharmacologic insulin infusion rate (1,200 mU/M2 per min) extremely high plasma insulin levels (-10,000 uU/ml) are reached within a couple of minutes. These insulin levels should rapidly saturate all plasma and tissue compartments with supraphysiologic insulin levels, and even under these conditions, activation ofglucose disposal was significantly slower in the obese group. This indicates that the mechanisms underlying this defect in the rate of insulin action lie at the level of the target cell. Although the cellular mechanisms responsible for the kinetic defects in insulin action in obesity are not elucidated by the current studies, certain inferences are possible. Decreased glucose transport activity has been described in adipocytes from insulinresistant obese subjects (20, 21) , and the magnitude of this decrease in glucose transport activity correlates quite well to the decrease in in vivo glucose disposal (20) . This suggests that a defect in the glucose transport system is responsible for the decrease in insulin's steady state effects on overall glucose disposal. Studies in adipocytes from obese animals have demonstrated a decrease in total cellular transporter number (22), consistent with the view that a decrease in transporter number exists in human obesity. A decrease in transporter number alone would not account for a slower rate of activation of insulin-stimulated glucose disposal, however, and one must postulate further abnormalities in the insulin action-glucose disposal stimulation sequence. Furthermore, this cellular defect is not common to all actions of insulin, since the rate of suppression of HGO was normal in the obese group. The cellular defect responsible for the slower rate of insulin action on glucose disposal thus most probably resides at a postbinding step and is specific for the components ofthe insulin action sequence that couple occupied insulin receptors to stimulation of glucose disposal.
Once the insulin infusion was discontinued, we were also able to measure the rate of deactivation of insulin's stimulatory effects on glucose disposal. Again, a striking relationship was noted between the magnitude of the insulin infusion and the fractional deactivation rate (Dm IGDR). As the insulin infusion rate was raised, higher Rd values were achieved, and the deactivation rates were progressively slower. In the normal subjects the D50 IGDR value thus was 34±3 min at the 15-mU insulin infusion and 78±5 min at the 120-mU infusion. The same relationship was noted in obesity, but for any given insulin infusion, the subsequent rate of deactivation of insulin action was faster in obesity. However, since the Rd values were directly related to the deactivation rates, and since Rd values are lower in obesity for any given insulin level, it was important to assess deactivation rates at comparable glucose disposal rates. When this was done (Fig. 5) Fig. 1 ) that would be necessary to achieve glucose disposal rates reached in control subjects at normal postprandial insulin levels.
In both groups, general relationships were found between the kinetic aspects of insulin action and the ultimate magnitude of the steady state glucose disposal rate. The higher the insulin infusion rate, the greater the steady state IGDR values and the faster the rate of insulin action. The rate of deactivation of insulin's effects were slower when the steady state IGDR was higher. These findings are consistent with in vitro studies ofthe kinetics of insulin action (24) (25) (26) (27) , as well as the available in vivo data (3, 8, 28, 29) . In vitro measurements of glucose transport in rat adipocytes (24) thus have demonstrated an inverse relationship between the height ofthe steady state insulin-stimulated glucose transport activity and the rate of glucose transport stimulation, such that the higher the ultimate level of glucose transport attained, the faster is the rate of activation of insulin action. Furthermore, the higher the insulin-stimulated rate of glucose transport achieved, the slower was the rate of deactivation of insulin action (25) (26) (27) . The in vivo relationships demonstrated in the current studies between rate of activation, deactivation, and steady state IGDR, thus conform well to the in vitro relationships between the kinetics ofinsulin action on glucose transport and the steady state effects of insulin on transport stimulation. In vivo studies are also consistent with the current results.
Earlier studies by Rabinowitz and Zierler (3) , using the forearm perfusion technique, described a dissociation between the decay ofplasma insulin and insulin's effect on forearm glucose uptake and called this phenomenon the "memory effect of insulin." Subsequent in vivo studies (8, 28, 29) confirmed these observations showing that the decay rate of insulin in plasma was much more rapid than deactivation of insulin's effects on peripheral glucose uptake and suppression of HGO. Gray et al. (8) carried out studies in normal subjects, and showed that the rate of dissipation of insulin action on glucose disposal was faster when lower steady state effects of insulin were achieved.
Insulin pharmacokinetics were remarkably similar in the obese and normal groups, indicating that differences in insulin clearance, compartmentalization, or access to tissue sites of action do not explain the kinetic abnormalities of insulin's biologic effects in obesity. The half times of approach to steady state, the steady state insulin values, and the plasma insulin decay curves thus were the same between the normal and obese groups at each insulin infusion rate. These findings are in agreement with those already reported in the literature. A number of different models have been proposed to describe insulin kinetics in man (28) (29) (30) (31) (32) (33) (34) . Sherwin et al. (28) proposed a three-compartment model where the plasma compartment rapidly exchanges with a liver compartment and slowly exchanges with the interstitial space. McGuire et al. did not detect differences in insulin kinetics between normal, obese, diabetic, and elderly subjects (31) using this model. Other studies in obese and normal subjects have also failed to find any alteration in the metabolic clearance rate for insulin in obesity (1, 2, 35). Sodoyez et al. (36) and Phillipe et al. (37) used an in vivo approach to study the relationship between plasma insulin and the kinetics of insulin binding and dissociation and found extremely close temporal relationships with only a 1-2-min lag period between insulin turnover in plasma, and turnover at tissue receptor sites. A slower rate of onset of insulin action in the current studies was observed in the obese subjects even at suprasaturating insulin levels (Figs. 3  and 4) . Taken together, these findings argue that the kinetic defects in insulin action observed in the present study are not related to insulin pharmacokinetics or the kinetics of insulin binding to target tissue receptors.
The effects of insulin to suppress HGO are clearly decreased in obesity, but several important differences exist between resistance to insulin's hepatic effects compared with the resistance to insulin stimulation of peripheral glucose disposal. Although the steady state effects of insulin to suppress HGO are less in obesity, these differences are only seen at submaximal insulin levels, and the magnitude ofthis defect is relatively modest compared to the decrease in insulin-stimulated glucose disposal. Since 100% suppression ofHGO is seen in both groups at higher insulin levels (>100 ,U/ml in normals and .300 ,U/ml in obese), the hepatic insulin resistance in obesity is manifested only by decreased insulin sensitivity, whereas the peripheral defect involves both decreased sensitivity and decreased maximal responsiveness. At all insulin levels, the rate of suppression of HGO was faster than stimulation of glucose disposal in both groups. Furthermore, in constrast to stimulation of glucose disposal, the rate of suppression of HGO by insulin was normal in obesity. The hepatic insulin resistance in obesity (decreased insulin sensitivity with normal rate of onset of insulin action) thus is compatible with the decrease in insulin receptors, particularly liver membrane receptors (38) , which have been reported in human obesity. In contrast, the resistance to insulin-stimulated glucose disposal involves decreased insulin sensitivity, decreased maximal responsiveness, and a slower rate of activation of insulin action; this is best explained by decreased insulin receptors, and more importantly, by decreased insulin action at a postbinding step. Of interest is the finding that the rate of recovery of HGO from insulin's suppressive effects is more rapid in obesity and, in view of the phasic manner in which insulin is normally secreted, this could have considerable functional significance in terms of altered glucose tolerance. It is tempting to speculate that the reduced glucagon suppression and more rapid return of glucagon to basal levels mediates the rapid recovery of HGO after the insulin infusions were stopped. Indeed the basal hyperglucagonemia and relatively impaired suppression ofglucagon levels by the insulin infusions in obesity may contribute to all of the aspects of hepatic insulin resistance in this condition. Taken together, the present results show that in obesity, resistance to insulin suppression of HGO is quantitatively mild compared to peripheral insulin resistance. Additionally, qualitative differences exist suggesting that decreased insulin receptors and relative hyperglucagonemia underlie the hepatic insulin resistance, whereas decreased insulin receptors plus postbinding defects in insulin action cause the peripheral insulin resistance.
In summary, the current studies demonstrate new aspects of the insulin-resistant state in human obesity. The data show that not only are the steady state effects of insulin reduced in obesity, but there are also marked kinetic alterations in the rates ofinsulin action to stimulate glucose disposal and suppress HGO. Since insulin is normally secreted in a phasic manner and steady state biologic effects of this hormone are probably not achieved under physiologic circumstances, we postulate that these kinetic abnormalities ofinsulin action in insulin-resistant obese subjects, represent a functionally important aspect of the insulin resistance, and may be the dominant manifestation of the insulin resistance in the physiologic, meal eating state.
